TIMOTHY POQUETTE: Open Payments
NPI 1427613447 · LAFAYETTE, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,115 in 59 payments from 16 companies in 2025. Trend: 2023 $782 · 2024 $803 · 2025 $1,115
Food & beverage: $1,115
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 17 | $221 |
| Alkermes, Inc. | 6 | $174 |
| Otsuka America Pharmaceutical, Inc. | 10 | $157 |
| Braeburn Inc. | 4 | $148 |
| Axsome Therapeutics, Inc. | 4 | $76 |
| Teva Pharmaceuticals USA, Inc. | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $35 |
| Lundbeck LLC | 2 | $34 |
| E.R. Squibb & Sons, L.L.C. | 2 | $34 |
Products named: VRAYLAR, BRIXADI, ABILIFY ASIMTUFII, LYBALVI, Sunosi, ARISTADA, ABILIFY MAINTENA, UZEDY.
Industry payments across IN — which companies pay providers there.
